摘要
乳腺癌是一种常见的女性恶性肿瘤,以中老年患者居多,近年来发病率逐年升高,且趋于年轻化。该病早期症状不明显,一旦有临床表现,往往已是中晚期,错过了最佳治疗时间。目前临床上常规用于早期乳腺癌筛查的血清标志物:糖类抗原(carbohydrate antigen 153,CA153)、癌胚抗原(carcinoembryonic antigen,CEA)与乳腺癌抗原(breast cancer antigen 225,BCA225)等均存在特异性差或敏感性低等缺陷。此外,临床上对乳腺癌的治疗虽已取得较大进展,但是固有的或后天获得的耐药性以及肿瘤细胞的转移会导致患者的治疗效果不佳最终死亡仍是目前待解决的难题。最新的研究表明外泌体在乳腺癌的发生发展中发挥重要作用,且具备乳腺癌诊疗生物标志物的潜能。因此,深入研究外泌体与乳腺癌的关系,将有助于提高乳腺癌诊疗效率。
Breast cancer is a common female malignancy, and most of the patients were elderly. The incidence of breast cancer has increased in recent years and has become much younger. The early symptoms of the disease are not obvious, and once clinical manifestation is present, it is often in the middle and late stage, missing the optimal treatment time. At present, the serum markers routinely used in early screening of breast cancer（CA153, CEA, BCA225 and so on） are all with drawbacks of low specificity or sensitivity. In addition, although the clinical treatment for breast cancer has made great progress, it＇s still a problem to be solved at present that the inherent or acquired drug resistance and transfer of tumor cells can lead to poor curative effect and the final death. Recent studies have shown that exosome plays an important role in the development of breast cancer and has the potential to be a biomarker for breast cancer＇s diagnosis and treatment. Therefore, further study on the relationship between exosomes and breast cancer will help to improve breast cancer diagnosis and treatment efficiency.
作者
蔡婉
李世宝
CAI Wan;LI Shibao(School of Medical Technology,Xuzhou Medical University,Xuzhou Jiangsu 221000;Department of Clinical Laboratory,The Affiliated Hospital of Xuzhou Medical University,Xuzhou Jiangsu 221004,China)
出处
《临床与病理杂志》
2018年第9期1997-2002,共6页
Journal of Clinical and Pathological Research
基金
江苏省"六大人才高峰"资助基金(2017-WSW-065)~~
